Immunotherapy using antibodies to inhibit the binding of Programmed Death Ligand 1 (PD-L1) to Programmed Death Receptor 1 (PD-1) has significantly changed the treatment landscape for advanced NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.